NDVAF vs OASMY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NDVAF is a Hold and OASMY is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NDVAF’s FA Score shows that 0 FA rating(s) are green whileOASMY’s FA Score has 0 green FA rating(s).
- NDVAF’s FA Score: 0 green, 5 red.
- OASMY’s FA Score: 0 green, 5 red.
Price Growth
NDVAF (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while OASMY (@Pharmaceuticals: Other) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -5.07%. For the same industry, the average monthly price growth was -7.87%, and the average quarterly price growth was -11.90%.
Reported Earning Dates
OASMY is expected to report earnings on Nov 21, 2024.
Industries' Descriptions
@Pharmaceuticals: Other (-5.07% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| NDVAF | OASMY | NDVAF / OASMY | |
| Capitalization | 3.51M | 12.8M | 27% |
| EBITDA | -5.09M | -88.39M | 6% |
| Gain YTD | -67.266 | 150.000 | -45% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 34.9M | 1.02M | 3,438% |
| Total Cash | 2.82M | 119M | 2% |
| Total Debt | 21.9M | 7.89M | 277% |
NDVAF | OASMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 81 Overvalued | 39 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 95 | |
PRICE GROWTH RATING 1..100 | 81 | 34 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 95 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
OASMY's Valuation (39) in the null industry is somewhat better than the same rating for NDVAF (81). This means that OASMY’s stock grew somewhat faster than NDVAF’s over the last 12 months.
OASMY's Profit vs Risk Rating (100) in the null industry is in the same range as NDVAF (100). This means that OASMY’s stock grew similarly to NDVAF’s over the last 12 months.
OASMY's SMR Rating (95) in the null industry is in the same range as NDVAF (98). This means that OASMY’s stock grew similarly to NDVAF’s over the last 12 months.
OASMY's Price Growth Rating (34) in the null industry is somewhat better than the same rating for NDVAF (81). This means that OASMY’s stock grew somewhat faster than NDVAF’s over the last 12 months.
OASMY's P/E Growth Rating (100) in the null industry is in the same range as NDVAF (100). This means that OASMY’s stock grew similarly to NDVAF’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| STMDX | 38.97 | 0.10 | +0.26% |
| Sterling Capital Real Estate I | |||
| GAOFX | 20.36 | -0.16 | -0.78% |
| JPMorgan Global Allocation R4 | |||
| WAEMX | 2.99 | -0.03 | -0.99% |
| Wasatch Emerging Markets Small Cap Inv | |||
| WVALX | 59.13 | -1.10 | -1.83% |
| Weitz Large Cap Equity-Investor Cl | |||
| APGAX | 101.16 | -2.75 | -2.65% |
| AB Large Cap Growth A | |||
NDVAF and
Correlation & Price change
A.I.dvisor tells us that NDVAF and ZLSCF have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NDVAF and ZLSCF's prices will move in lockstep.
| Ticker / NAME | Correlation To NDVAF | 1D Price Change % | ||
|---|---|---|---|---|
| NDVAF | 100% | N/A | ||
| ZLSCF - NDVAF | 25% Poorly correlated | N/A | ||
| MEDIF - NDVAF | 9% Poorly correlated | -1.64% | ||
| MRMD - NDVAF | 4% Poorly correlated | -6.76% | ||
| OASMY - NDVAF | 2% Poorly correlated | N/A | ||
| NXEN - NDVAF | 2% Poorly correlated | N/A | ||
More | ||||
OASMY and
Correlation & Price change
A.I.dvisor tells us that OASMY and MVMDF have been poorly correlated (+9% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OASMY and MVMDF's prices will move in lockstep.
| Ticker / NAME | Correlation To OASMY | 1D Price Change % | ||
|---|---|---|---|---|
| OASMY | 100% | N/A | ||
| MVMDF - OASMY | 9% Poorly correlated | -1.30% | ||
| MKGAF - OASMY | 4% Poorly correlated | -1.32% | ||
| NXEN - OASMY | 4% Poorly correlated | N/A | ||
| NXSCF - OASMY | 4% Poorly correlated | -3.18% | ||
| PCLOF - OASMY | 2% Poorly correlated | +0.95% | ||
More | ||||